Prostate cancer risk in men with prostate and breast cancer family history: Results from the REDUCE study (R1)

Journal of Internal Medicine

Volumn 272, Issue 1, 2012, Pages 85-92

  Thomas, J A ^a,b   Gerber, L ^a,b   Moreira, D M ^c   Hamilton, R J ^d   Banez L L ^a,b   Castro Santamaria, R ^e   Andriole, G L ^f   Isaacs, W B ^g   Xu, J ^h   Freedland, S J ^a,b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c The Arthur Smith Institute for Urology   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS HOSPITAL   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Family history; Prostate cancer; REDUCE

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FAMILY HISTORY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY; TUMOR VOLUME;

5-ALPHA REDUCTASE INHIBITORS; AGED; ANTICARCINOGENIC AGENTS; AZASTEROIDS; BREAST NEOPLASMS; COHORT STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84862781644     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02504.x     Document Type: Article

References (28)

1. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 2003; 107: 797-803.
2. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003; 91: 789-794.
3. Chen YC, Page JH, Chen R, Giovannucci E. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate 2008; 68: 1582-1591.
4. Makinen T, Tammela TL, Stenman UH et al. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 2002; 20: 2658-2663.
5. Bratt O, Garmo H, Adolfsson J et al. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 2010; 102: 1336-1343.
6. Bermejo JL, Hemminki K. Familial risk of cancer shortly after diagnosis of the first familial tumor. J Natl Cancer Inst 2005; 97: 1575-1579.
7. Cerhan JR, Parker AS, Putnam SD et al. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev 1999; 8: 53-60.
8. Rodriguez C, Calle EE, Tatham LM et al. Family history of breast cancer as a predictor for fatal prostate cancer. Epidemiology 1998; 9: 525-529.
9. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86: 1600-1608.
10. Isaacs SD, Kiemeney LA, Baffoe-Bonnie A, Beaty TH, Walsh PC. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995; 87: 991-996.
11. Hayes RB, Liff JM, Pottern LM et al. Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer 1995; 60: 361-364.
12. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-1202.
13. Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ. Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 2011; 14: 326-331.
14. McCahy PJ, Harris CA, Neal DE. Breast and prostate cancer in the relatives of men with prostate cancer. Br J Urol 1996; 78: 552-556.
15. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337-347.
16. Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR. Familial patterns of prostate cancer: a case-control analysis. J Urol 1991; 146: 1305-1307.
17. Ghadirian P, Howe GR, Hislop TG, Maisonneuve P. Family history of prostate cancer: a multi-center case-control study in Canada. Int J Cancer 1997; 70: 679-681.
18. Whittemore AS, Wu AH, Kolonel LN et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995; 141: 732-740.
19. Ahn J, Moslehi R, Weinstein SJ, Snyder K, Virtamo J, Albanes D. Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Cancer 2008; 123: 1154-1159.
20. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121: 1571-1578.
21. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
22. Bratt O, Kristoffersson U, Lundgren R, Olsson H. Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer 1999; 35: 272-277.
23. Hemminki K, Czene K. Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer 2002; 95: 1346-1353.
24. Gronberg H, Damber L, Damber JE. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996; 77: 138-143.
25. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Familial risks of breast and prostate cancers: does the definition of the at risk period matter? Eur J Cancer 2010; 46: 752-757.
26. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 1992; 305: 855-857.
27. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22: 735-742.
28. Gallagher DJ, Gaudet MM, Pal P et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-2121.